Nicholas Girard, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment of patients with non–small cell lung cancer, highlighting data from the phase 3 TROPION-Lung01 study.
Data from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded "exciting" results with experts hailing the drug as standard of care in various settings.